Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study

OBJECTIVE: To evaluate the efficacy of fremanezumab in patients with chronic migraine (CM) and moderate to severe depression. BACKGROUND: Fremanezumab, a fully humanized monoclonal antibody that selectively targets calcitonin gene–related peptide, has been approved for the preventive treatment of mi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lipton, Richard B., Cohen, Joshua M., Galic, Maja, Seminerio, Michael J., Yeung, Paul P., Aycardi, Ernesto, Bigal, Marcelo E., Bibeau, Kristen, Buse, Dawn C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Submissions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251795/
https://www.ncbi.nlm.nih.gov/pubmed/33891348
http://dx.doi.org/10.1111/head.14097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251795/
https://www.ncbi.nlm.nih.gov/pubmed/33891348
http://dx.doi.org/10.1111/head.14097

Ejemplares similares